Search PubMed⌕ Search

Biomedical subjects

H Hosoi

Publications and source records attributed to H Hosoi.

At least 91 records · Page 5Linked to original sources
PubMed1989

[Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].

The influence of OK-432 on the activation of UFT, consisting of tegafur and Uracil, was examined in patients with gastric cancer and colonic cancer. In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases). As the results, in the groups of patients given OK-432, the concentration in gastric cancer tissue was 0.093 +/- 0.067 microgram/g and that in colonic cancer was 0.098 +/- 0.058 microgram/g. Both values exceeded 0.05 microgram/g which is considered to be the effective intratumor 5-FU concentration. No difference was observed in these cases given UFT alone. The ratio of intratumor 5-FU concentration vs. that of normal tissue was 2.5 for gastric cancer and 2.7 for colonic cancer and the ratio of tumor vs. serum 5-FU concentrations was 8.5 for gastric cancer and 10.9 for colonic cancer. No difference was also observed in these values in cases given UFT alone. From above results, it seemed that the clinical dose of OK-432 2KE 2/W had no influence on the activation of UFT, so that the combination therapy of UFT and OK-432 was found to be clinically useful.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

[Application of straight chain fatty acid analog IPPA [omega-(p-iodophenyl)-pentadecanoic acid] for myocardial imaging--using acute myocardial infarction model].

Application for myocardial imaging and fundamental experiments were studied using straight chain fatty acid analog IPPA [omega-(p-iodophenyl)-pentadecanoic acid]. Biodistribution of IPPA in rabbits (n = 6) shows the accumulation in liver was maintained 81.0% at 30 minutes, while the accumulations of heart, lungs and kidneys were 30.0%, 10.0% and 15.0% respectively. Especially the accumulation of heart decreased rapidly from 48.0% at 3 minutes to 30.0% at 30 minutes, reflecting the effect of beta oxidation. On the other hand, in the acute myocardial infarction mode (n = 6), with occlusion in left anterior descending coronary artery, all 6 cases showed defect images at the corresponding areas after injection of 3 mCi of IPPA. Myocardial imaging with IPPA should be useful not only for myocardial metabolic diseases (cardiomyopathy etc.) but also for ischemic heart disease.

Animals↗
PubMed1989

[A case of metastatic lung tumor mimicking left atrial myxoma by echocardiography].

We report a case of lung metastatic tumor originated from submandibular osteosarcoma, which shows rare advancement and findings. This lung metastatic tumor advanced from left lower lung to left atrium through the left lower pulmonary vein, which penetrated to the left ventricle in the diastolic phase mimicking left atrial myxoma. 67Ga-citrate images showed that hot accumulation were recognized behind the heart in planar image and clear advancement from the lung to the heart in the SPECT image. 67Ga-citrate SPECT image should be available for cardiac tumors.

Adult↗
PubMed1988

Schwannian cell differentiation of human neuroblastoma cell lines in vitro induced by bromodeoxyuridine.

In normal development the neural crest gives rise to sympathetic neuroblasts, sensory and autonomic ganglia, as well as Schwann cells. One tumor arising from this tissue is the neuroblastoma (NB), a malignancy of the adrenergic component of the sympathetic nervous system. Recent histological studies have shown that neuroblastomas can present with a schwannian cell component, rich in S100 protein. We have investigated the differentiation of NB cell lines, GOTO and RT-LN-1, into a schwannian cell phenotype using bromodeoxyuridine (BrdU). This agent induced morphological changes in these cell lines. Flat-epithelial cells were identified in the GOTO cell line and both flat-epithelial and neuronal phenotypes were found in the RT-LN-1 cell line. S100 protein (beta-Subunit) was induced in both cell lines after 18-25 days of BrdU treatment as determined by enzyme-linked immunoassay. In addition increase in the beta-subunit of S100 protein was identified in BrdU-treated flat-epithelial cells by indirect immunofluorescence using a monoclonal antibody specific for the beta-subunit of the protein. Cyclic nucleotide phosphodiesterase activity significantly increased in both BrdU-treated NB cell lines, as compared with nontreated cells. However no significant increase of glial fibrillary acidic protein in BrdU-treated cells was found either by enzyme-linked immunoassay or indirect immunofluorescence using a monoclonal antibody to glial fibrillary acidic protein. Thus, cells with Schwann cell characteristics can clearly be identified in the neuroblastoma cell lines after BrdU treatment. Fluorescence-activated cell sorting analysis revealed no quantitative changes in cell membrane antigens recognized by monoclonal antibodies UJ-13A (neuroectodermal associated antigen) and anti-Thy-1 (Thy-1) on BrdU treatment. In contrast, UJ-127-11 (neuroectodermal associated) decreased, and W6/32 and BB7.7 (HLA-ABC) and BBM.1 (beta 2-microglobulin) markedly increased in both BrdU-treated cell lines. No induction of L243 (HLA-DR), B7/21 (HLA-DP), and Genox 3.55 (HLA-DQ) was noted. The increased HLA-ABC (HLA class I) antigen may enable BrdU-treated NB cells to be recognized by cytotoxic T-cells. This may be related to the pathological evidence that NB patients whose tumors are rich in S100 protein have a better prognosis. Further studies on the potential of differentiation agents to induce a phenotypic change, that is associated with an improved prognosis for NB patients, are required.

2',3'-Cyclic-Nucleotide Phosphodiesterases↗